Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis
Abstract Background Mineral bone disease constitutes a common complication of post-kidney transplantation, leading to great disability. As there is no consensus on the optimal treatment for post-kidney transplant recipients (KTRs), we aimed to evaluate the efficacy and safety of bisphosphonate and its combined therapies. Methods We incorporated relevant trials to perform a network meta-analysis from direct and indirect comparisons. We searched PubMed, Embase and the CENTRAL and the reference lists of relevant articles up to August 1, 2017, for randomized controlled trials. The primary outcome was bone mineral density (BMD) change at the femoral neck and the lumbar spine. Results From a total of 864 citations, 18 randomized controlled trials with a total of 1200 participants were included. Five different regimens were considered. Bisphosphonate plus calcium revealed a significant gain in percent BMD change than calcium alone at the femoral neck (mean difference (MD), 5.83; 95% credible interval (CrI), 1.61 to 9.27). No significant difference was detected when restricting to absolute terms. At the lumbar spine, bisphosphonate and calcium with or without vitamin D analogs outperformed calcium solely (MD, 0.07; 95% CrI, 0.00 to 0.13; MD, 0.06; 95% CrI, 0.02 to 0.09). Compared to calcium with vitamin D analogs, adding bisphosphonate was associated with marked improvement (MD, 0.03; 95% CrI, 0.00 to 0.05). Considering percent terms, combination of bisphosphonate with calcium and vitamin D analogs showed greater beneficial effects than calcium alone or with either vitamin D analogs or calcitonin (MD, 10.51; 95% CrI, 5.92 to 15.34; MD, 5.48; 95% CrI, 2.57 to 8.42; MD, 6.39; 95% CrI, 0.55 to 12.89). Both bisphosphonate and vitamin D analogs combined with calcium displayed a notable improvement compared to calcium alone (MD, 7.24; 95% CrI, 3.73 to 10.69; MD, 5.02; 95% CrI, 1.20 to 8.84). Conclusions Our study suggested that additional use of bisphosphonate was well-tolerated and more favorable in KTRs to improve BMD..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
BMC Nephrology - 19(2018), 1, Seite 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan Yang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Bisphosphonates |
|---|
| doi: |
10.1186/s12882-018-1076-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ003742628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ003742628 | ||
| 003 | DE-627 | ||
| 005 | 20230503083506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12882-018-1076-1 |2 doi | |
| 035 | |a (DE-627)DOAJ003742628 | ||
| 035 | |a (DE-599)DOAJae39782ce7164e0eadc5019534b1c63d | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC870-923 | |
| 100 | 0 | |a Yan Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Mineral bone disease constitutes a common complication of post-kidney transplantation, leading to great disability. As there is no consensus on the optimal treatment for post-kidney transplant recipients (KTRs), we aimed to evaluate the efficacy and safety of bisphosphonate and its combined therapies. Methods We incorporated relevant trials to perform a network meta-analysis from direct and indirect comparisons. We searched PubMed, Embase and the CENTRAL and the reference lists of relevant articles up to August 1, 2017, for randomized controlled trials. The primary outcome was bone mineral density (BMD) change at the femoral neck and the lumbar spine. Results From a total of 864 citations, 18 randomized controlled trials with a total of 1200 participants were included. Five different regimens were considered. Bisphosphonate plus calcium revealed a significant gain in percent BMD change than calcium alone at the femoral neck (mean difference (MD), 5.83; 95% credible interval (CrI), 1.61 to 9.27). No significant difference was detected when restricting to absolute terms. At the lumbar spine, bisphosphonate and calcium with or without vitamin D analogs outperformed calcium solely (MD, 0.07; 95% CrI, 0.00 to 0.13; MD, 0.06; 95% CrI, 0.02 to 0.09). Compared to calcium with vitamin D analogs, adding bisphosphonate was associated with marked improvement (MD, 0.03; 95% CrI, 0.00 to 0.05). Considering percent terms, combination of bisphosphonate with calcium and vitamin D analogs showed greater beneficial effects than calcium alone or with either vitamin D analogs or calcitonin (MD, 10.51; 95% CrI, 5.92 to 15.34; MD, 5.48; 95% CrI, 2.57 to 8.42; MD, 6.39; 95% CrI, 0.55 to 12.89). Both bisphosphonate and vitamin D analogs combined with calcium displayed a notable improvement compared to calcium alone (MD, 7.24; 95% CrI, 3.73 to 10.69; MD, 5.02; 95% CrI, 1.20 to 8.84). Conclusions Our study suggested that additional use of bisphosphonate was well-tolerated and more favorable in KTRs to improve BMD. | ||
| 650 | 4 | |a Kidney transplant | |
| 650 | 4 | |a Bisphosphonates | |
| 650 | 4 | |a Bone mineral density | |
| 650 | 4 | |a Network meta-analysis | |
| 653 | 0 | |a Diseases of the genitourinary system. Urology | |
| 700 | 0 | |a Shi Qiu |e verfasserin |4 aut | |
| 700 | 0 | |a Linghui Deng |e verfasserin |4 aut | |
| 700 | 0 | |a Xi Tang |e verfasserin |4 aut | |
| 700 | 0 | |a Xinrui Li |e verfasserin |4 aut | |
| 700 | 0 | |a Qiang Wei |e verfasserin |4 aut | |
| 700 | 0 | |a Ping Fu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t BMC Nephrology |d BMC, 2003 |g 19(2018), 1, Seite 12 |w (DE-627)DOAJ000122297 |x 14712369 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:1 |g pages:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12882-018-1076-1 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ae39782ce7164e0eadc5019534b1c63d |z kostenfrei |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1186/s12882-018-1076-1 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1471-2369 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 1 |h 12 | ||